Novast Laboratories (Stock Code: 301569) will land on ChiNext board on October 15, 2026.

Novast Laboratories is publicly offering 133.739563 million shares, including 133.739563 million IPO shares offered at 7 yuan per share and raising funds of 936 million yuan. The post-public-offering share capital of Novast Laboratories is 891.597091 million shares in total. Novast Laboratories, Limited principally engages in the research and development, production, and sales of complex pharmaceutical formulations. In 2025, its operating income reached 895 million yuan with the net profit of 227.819 million yuan.